Form 4: BioMarin Executive Charles Guyer Reports Stock Transactions

Charles Greg Guyer, EVP and Chief Technical Officer of BioMarin Pharmaceutical Inc., reports acquisition of stock options and restricted stock units, as well as disposition of shares to cover tax obligations.

Summary

• On March 15, 2024, Charles Greg Guyer, EVP and Chief Technical Officer of BioMarin Pharmaceutical Inc., acquired 10,550 shares of common stock as restricted stock units.
• On the same date, Guyer disposed of 20,424 shares of common stock at a price of $83.87.
• These transactions resulted in Guyer beneficially owning 78,327 shares of common stock following the reported transactions.
• Guyer also acquired 23,630 stock options with an exercise price of $83.87, exercisable starting March 15, 2025.
• The stock options expire on March 14, 2034.
• The transactions were reported on March 19, 2024.

Sentiment

Score: 6

Explanation: Neutral sentiment as the document primarily reports routine stock transactions. The acquisition of stock options and restricted stock units is a positive sign, but the disposition of shares offsets this to some extent.

Positives

• The acquisition of restricted stock units and stock options suggests continued alignment of the executive's interests with the company's long-term performance.

Negatives

• The disposition of 20,424 shares may be perceived negatively, although it is likely related to covering tax obligations associated with the vesting of restricted stock units.

Risks

• There are no specific risks highlighted in this document, as it primarily reports stock transactions by an executive.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common forms of executive compensation in the biotechnology industry, used to incentivize performance and align management's interests with shareholders.
• The vesting schedule of the options (12/48th on March 15, 2025 and 1/48th monthly thereafter) is a typical vesting arrangement.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize similar equity-based compensation strategies for their executives.

Stakeholder Impact

• The transactions may have a minor impact on shareholders' perception of the company, depending on how they interpret the executive's stock activity.
• Employees may view the stock option grants as a positive sign of the company's commitment to its employees.

Key Dates